Hi all
pretty new to all this. I have pumped some into Deltex - looks like a strong product with good growth. Could be a steady gainer.
Does anyone else have this, and anyone have some research on it? Someone with more experience than me!
thanks in advance.
Grajul

Added a few more today @ this very low level, it's been a while since they were this price. Good luck all.
2517

I wonder how the NHS Technology Adoption Hub review is going, they have had 3 complete months now, maybe some feedback is due from them.
2517

Right on cue. Looks to be doing very well in all aspects, the only blip is SupraQ sales. Latin America becoming increasingly aware of DEMG's products.
2517

Significant progress in all of its key markets.
Anticipate that sales for the year will be in excess of 4.1 million.

Nice increase from 3,511,000 previous year. Outlook is looking very good, although
we are still it appears looking for that big breakthrough.
Be interesting to see if costs per item have decreased, as presumably with increase production they will have.
Still more patience needed, but a good pre close statement.
Looking forward to full results.

Deltex Medical (DEMG-AIM) S.P. 19.00p. Market Cap 20.12m
Our share club has held a position with DEMG for some time now, on which we are showing a profit. Of 1.15%. Hot news just in from DEMG

Positive scientific review of CardioQ technology published

Pre-close update on the year ended 31 December 2007

To find out more about .DEMG click onto www.deltexmedical.com/.

myway, previously you said (post 510) that at 23.25p you had a profit of 1.25% so you must have bought at 22.96p

Now you say that at 19.00p you have a profit of 1.15% so you must have bought at 18.78p

It is good to be in profit. I am hoping for a 400% profit at least.

Nice to see 3 directors buying, 70k in total.
2517

Thanks Art Dysg we are buying and selling as the markets trades

Deltex Medical (DEMG-AIM) S.P. 19.25p. Market Cap 20.12m

I was pleased to read the news last week that once more DEMG has a Positive scientific review of CardioQ technology published. CardioQ is the companys lead proven product

Marketing details from Pre-close update on the year ended 31 December 2007

"Deltex Medical continued to make significant progress during 2007 towards establishing the CardioQ as a global standard of care. We now have increasing momentum in the US and other key international markets as well as in the UK."

To find out more about .DEMG click onto www.deltexmedical.com/.

How depressing is this, the shares wavered around the same range for the last 4 years, you must all be buying low and waiting for the upwards spike selling and repeating yourselves....

Re the RNS.

Just how many more positive results re health and cost benefits must there be before the NHS take notice and positive action re this no brainer.
The RNS hasn't even moved the SP due to most feeling as if its the usual banging of heads of the proverbial brick wall.

Yet another trial result. BUT this one does not show how much the result was down to the laparoscopic surgery or the CardioQ, as the CardioQ was not used in the open surgery. So in reality it tells us nothing.
Still a big believe in the CardioQ but this does not imho enhance this believe.

The Company today announces that it has now made its first sale in connection with the NTAH.
Yet another update result, BUT this one is different.
IMHO as they now have a firm foothold re the NTAH, I feel this is finally the start of real progress in general use of the CardioQ.
I don't expect a sudden rush of further contracts, but I do expect from this release a far greater momentum in deals.

It has been mentioned on this thread several times that Private Hospitals in the UK, USA and other countries have no incentive to treat patients in such a manner as to procure their discharge earlier. The reasons stated for this are that the longer these patients stay in hospital the more money is made by these hospitals, both in length of stay charges and treatment costs as these are paid by either the patients themselves or insurance schemes.
With completion in the insurance industries that cover medical situations increasing at a fast pace, to me this augment is becoming a bit out dated.
There are an increasing number of patients going private in the UK (although this might obviously be reversed due to the credit squeeze) and as a result more medical facilities are offering private treatments.
Within a 20 mile radius of my home there are at least 3 different private medical hospitals offering a huge diversity of treatments. The private medical insurance I have has changed the hospital it uses 3 times in the last 10 years, presumably down to cost.
Surely if there is this amount of competition among both insurance companies and hospitals it must be beneficial to all that hospital stay times are as short as possible.
In countries that have their medical facilities mainly privately funded no doubt this incentive is even more in evidence.
I am obviously aware that the more these hospitals and insurance companies can charge and get away with they will do so, but if you look at other industries such as supermarkets, competition is the main leveler of low costs.
Get the CardioQ into your hospital, cut in patient times and get more customers makes sense to me.
All IMHO of course.

RNS.

First protocols for routine use of the CardioQ(TM) in intensive care established
at leading acute hospital in the USA.

This just has to be the spark that lights the CardioQ fire, surely.

Some buying today but the sp has hovered aroung these sort of levels for such a long time. I will hang on for the benefits, but I imagine they are some way off.
2517

The latest info from the trial are that the CardioQ halved the average recovery time of post operative patient.
The general use of the CardioQ is not rocket science, and yet the medical establishment still procrastinate (to defer action; delay: to procrastinate until an opportunity is lost, to put off till another day or time or as I see the NHS management , finger up rectum, too much of a mind numbing act to take it out) as the UK medical establishment does.
Been tempted to top up for quite a while now. This RNS decided it for me.

Re today's rns---This is now beginning to look much more promising.
2517

Yes looks like we have lift off. Hopefully the roll out of full contracts will now start to gather speed. Patience appears to be finally getting results.

THE COUNT--->GREEKMAN

Hi.

Wrt your post, no 525, I'd just like to add that ultimately, no doctor will use any treatment he is unhappy with. Medical ethics play a great role in determining treatment. And how do medical pros decide what constitutes adequate treatment....their personal experience in conjunction with evidence based medicine.

The evidence for using the CardioQ is all there in, what I am told, is a far greater number of random clinical studies published in major and peer reviewed medical journals, than any other new medical technology. In other words, what you and I already know...it's a no-brainer.

It has also had strong and independent backing from the AHRQ study in the USA, which was a study effectively commissioned by the US government. It was also a study of studies and its conclusion was as positive as you can get.

Against such a positive backdrop, It will be the medical insurers that will push hard to bring down their own costs. After all, it is they who reimburse the hospital and the doctors. It is certainly in their interests to push for shorter hospital stays, even if it wasn't that of the actual hospital's.

The medical insurers are not in a position to push up their own premiums to the patient endlessly...even in the USA, there is massive political debate on the cost of health insurance. So any initiative that can drive costs down will be welcomed by the powers that count.

But on top of this, there will be larger studies that hopefully will show a statistically significant effect on actual mortality when the CardioQ is in use. Then it will become almost a necessity on medical ethical grounds.

Finally though, and most expecially in the USA, if a patient, or group of patients can show that any hospital kept them in for longer when there was a medically acceptable means of reducing hospital stays easily and readily available, and actually backed by the medical insurers, the hospital wil have its arse sued off.


Regarding your post no 528.

The medics themselves do not need much more convincing of the need to use the CardioQ. Even the National Institute for Health and Clinical Excellence (NICE) backs its use. I know that over a year ago, actual clinical demand within the UK ran at over 300,000 potential procedures pa. It wil be even higher now.

What does thsi mean exactly? It means that doctors want to use the CardioQ on patients for that many procedures but are unable to do so because those holding the purse strings will not allow them to do so.This is mainly down to the farcical and irrational methods being used in our hospitals to pay for this...the use of the crazy method of solo budgeting.

But depite all this, we are slowly getting there (slower than you or I want), and there will be well in excess of 30,000 UK patients benefitting from th euse of the CardioQ.

Regards and keep the faith,

THE COUNT!

RNS looking good.

Everything that should be increasing is.

Turnover 50%, UK/USA sales 50%, Cash available approx 85%, margins from 66.3% to 70.0% plus progress in all markets.

Those sections of the results that show increases in negatives are almost insignificant and for obvious reasons.

Cash burn up by approx 33% but due to increase in pushing sales and R&D that was to be expected, as was the slight increase in operating loss for the same reasons.

The best part of the results must be the increase of sales almost month on month as 2007 progressed. Even at the present rate of increase 2008 look to be lining up for profitability.

Would liked to see more cash available although it has increased from the previous year. Also with the extra cash to be raised, plus the increase that is bound to come both from present sale, replacements of probes and monitors in addition (hopefully) of initial base sales on the whole the prospects look excellent.

Let's just hope the market sees it that way.